HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication
E. Rodríguez de Santiago
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Search for more papers by this authorK. Velázquez Kennedy
Department of Hematology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Search for more papers by this authorM. García González
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
Search for more papers by this authorF. Gea Rodríguez
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
Search for more papers by this authorL. Téllez Villajos
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
Search for more papers by this authorE. Tavío Hernández
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Search for more papers by this authorCorresponding Author
A. Albillos
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain
E-mail: [email protected]Search for more papers by this authorE. Rodríguez de Santiago
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Search for more papers by this authorK. Velázquez Kennedy
Department of Hematology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Search for more papers by this authorM. García González
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
Search for more papers by this authorF. Gea Rodríguez
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
Search for more papers by this authorL. Téllez Villajos
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
Search for more papers by this authorE. Tavío Hernández
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Search for more papers by this authorCorresponding Author
A. Albillos
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain
E-mail: [email protected]Search for more papers by this authorCONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
- 1Schiavinato A, Zanetto A, Pantano G, et al. Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. J Viral Hepat. 2017; 24: 1168-1176.
- 2Persico M, Aglitti A, Caruso R, et al. Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma. Hepatology. 2018; 67(1): 48-55. https://doi.org/10.1002/hep.29364.
- 3Arcaini L, Besson C, Frigeni M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016; 128: 2527-2532.
- 4Reig M, Boix L, Bruix J. The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. Liver Int. 2017; 37(Suppl 1): 136-139.
- 5Saadi T, Khoury J. Is there a relationship between treatment with direct antiviral agents for HCV infection and the development of malignancies? J Clin Gastroenterol. 2017. https://doi.org/10.1097/MCG.0000000000000853.
Citing Literature
